Condition (MeSH)
Masked Hypertension
ClinicalTrials.gov lists 17 trials for Masked Hypertension or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
17 of the 17 trials are tagged with Masked Hypertension itself; the rest are tagged with a narrower condition beneath it.
When did Masked Hypertension trials start? (11)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2022 | 1 |
| 2021 | 1 |
| 2020 | 2 |
| 2019 | 1 |
| 2018 | 3 |
| 2017 | 1 |
| 2015 | 3 |
| 2014 | 2 |
| 2008 | 1 |
Showing 10 of 11 earlier years.
No forecast is made for this condition: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Masked Hypertension trials in? (4)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 3 | 2 |
| Phase 4 | 4 |
| Not applicable | 5 |
| Observational | 6 |
How many Masked Hypertension trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 1 |
| Completed | 6 |
| Withdrawn | 1 |
| Unknown status | 8 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which drugs are being tested for Masked Hypertension? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| "Mitiglinide" | 1 |
| Allisartan Isoproxil | 1 |
Interventions as named in the registry (6)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| "Liraglutide" and "Mitiglinide" | 1 |
| Carvedilol CR | 1 |
| Antihypertensive treatment will be stopped for 1 year unless hypertension recurrence | 1 |
| "Metformin" and "Mitiglinide" | 1 |
| Gastrodia and Uncaria Drink | 1 |
Showing 5 of 6 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Masked Hypertension? (32)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| No Increase in Masked Hypertension Prevalence in Children With Sickle Cell Disease in France. | American journal of hypertension | 2024 | Yes |
| Age-related patterns of ambulatory blood pressure in a large cohort of individuals referred to Italian community pharmacies: results from the templar project. | Journal of hypertension | 2023 | Yes |
| Sex Differences in Ambulatory Blood Pressure Levels and Subtypes in a Large Italian Community Cohort. | Hypertension (Dallas, Tex. : 1979) | 2023 | Yes |
| Machine Learning-Based Prediction of Masked Hypertension Among Children With Chronic Kidney Disease. | Hypertension (Dallas, Tex. : 1979) | 2022 | Yes |
| Comparison of intraoperative arterial blood pressure lability during general anaesthesia in masked, uncontrolled hypertensive and adequately controlled hypertensive patients: a prospective observational study. | Anaesthesiology intensive therapy | 2022 | Yes |
Showing 5 of 32 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: lead sponsors, serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.